Results 1 to 10 of about 734,275 (243)

Antiphospholipid Antibodies and Systemic Scleroderma

Turkish Journal of Hematology, 2013
Antiphospholipid antibodies (APLs) could be associated with an increased risk of vascular pathologies in systemic scleroderma. The aim of our study was to search for APLs in patients affected by systemic scleroderma and to evaluate their involvement in the clinical manifestations of this disease.We conducted a cross-sectional descriptive study, from ...
Blaise Felix Faye, Saliou Diop, Abibatou Sall, Awa Oumar Touré, Moussa Seck, Fatimata Ly, Alassane Diatta, Macoura Gadji, Tandakha Ndiaye Dieye   +8 more
doaj   +8 more sources

A Role of Myocardin Related Transcription Factor-A (MRTF-A) in Scleroderma Related Fibrosis. [PDF]

, 2015
In scleroderma (systemic sclerosis, SSc), persistent activation of myofibroblast leads to severe skin and organ fibrosis resistant to therapy. Increased mechanical stiffness in the involved fibrotic tissues is a hallmark clinical feature and a cause of ...
Abraham, D, Ahmed-Abdi, B, Denton, C, Lafyatis, R, Layne, MD, Nikitorowicz-Buniak, J, Ponticos, M, Shiwen, X, Smith, BD, Stratton, R, Suki, B, Takahashi, A   +11 more
core   +28 more sources

Definition of Naturally Processed Peptides Reveals Convergent Presentation of Autoantigenic Topoisomerase I Epitopes in Scleroderma. [PDF]

, 2020
ObjectiveAutoimmune responses to DNA topoisomerase I (topo I) are found in a subset of scleroderma patients who are at high risk for interstitial lung disease (ILD) and mortality.
Boin, Francesco, Cole, Robert N, Darrah, Erika, Fava, Andrea, Guhr, Tara, McMahan, Zsuzsanna H, O'Meally, Robert N, Shah, Ami A, Tiniakou, Eleni, Wigley, Fredrick M   +9 more
core   +1 more source

Oxidative stress in the pathogenesis of systemic scleroderma: An overview [PDF]

, 2018
Systemic sclerosis (SSc) is a rare disorder of the connective tissue characterized by fibrosis of the skin, skeletal muscles and visceral organs. Additional manifestations include activation of the immune system and vascular injury. SSc causes disability
Gambardella, Lucrezia, Giovannetti, Antonello, Malorni, Walter, Pietraforte, Donatella, Straface, Elisabetta, Vona, Rosa   +5 more
core   +1 more source

Systemic Sclerosis (Scleroderma) [PDF]

Laboratory Medicine, 2005
labmedicine.com November 2005 Volume 36 Number 11 LABMEDICINE 723 Systemic sclerosis is a chronic disease of unknown etiology characterized by abnormal accumulation of fibrous tissue in the skin and multiple organs.1 Scleroderma derives its name from the Greek words “sclerosis” (hardness) and “derma” (skin), thus aptly named “hard skin,” a feature that
M. Qasim Ansari, Adil I. Khan, Joseph S. Susa   +2 more
openaire   +2 more sources

Clinical and serological features of systemic sclerosis in a multicenter African American cohort: Analysis of the genome research in African American scleroderma patients clinical database. [PDF]

, 2017
Racial differences exist in the severity of systemic sclerosis (SSc). To enhance our knowledge about SSc in African Americans, we established a comprehensive clinical database from the largest multicenter cohort of African American SSc patients assembled
Boin, Francesco, Carns, Mary, Chung, Lorinda, Criswell, Lindsey A, Derk, Chris T, Domsic, Robyn T, Gladue, Heather, Goldberg, Avram, Gordon, Jessica K, Gourh, Pravitt, Hsu, Vivien, Jan, Reem, Kastner, Daniel L, Khanna, Dinesh, Mayes, Maureen D, Medsger, Thomas A, Morgan, Nadia D, Ramos, Paula S, Remmers, Elaine F, Saketkoo, Lesley A, Schiopu, Elena, Shah, Ami A, Shanmugam, Victoria K, Silver, Richard M, Steen, Virginia D, Trojanowski, Marcin A, Valenzuela, Antonia, Varga, John, Wigley, Fredrick M   +28 more
core   +1 more source

A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. [PDF]

, 2012
OBJECTIVE: A prospective observational study of mycophenolate mofetil (MMF) treatment in patients with diffuse progressive cutaneous systemic sclerosis (SSc) of recent onset.
Jimenez, Sergio A., Lee, MD, Jason B., Mendoza, MD, Fabian A., Nagle, Sarah J.   +3 more
core   +3 more sources

Clinical periodontal diagnosis

Periodontology 2000, EarlyView., 2023
Abstract Periodontal diseases include pathological conditions elicited by the presence of bacterial biofilms leading to a host response. In the diagnostic process, clinical signs such as bleeding on probing, development of periodontal pockets and gingival recessions, furcation involvement and presence of radiographic bone loss should be assessed prior ...
Giovanni E. Salvi, Andrea Roccuzzo, Jean‐Claude Imber, Alexandra Stähli, Björn Klinge, Niklaus P. Lang   +5 more
wiley   +1 more source

Assessment of tissue fibrosis in skin biopsies from patients with systemic sclerosis employing confocal laser scanning microscopy: an objective outcome measure for clinical trials? [PDF]

, 2010
OBJECTIVES: To obtain an objective, unbiased assessment of skin fibrosis in patients with SSc for use in clinical trials of SSc disease-modifying therapeutics.
Busquets, Joanna, Del Galdo, Francesco, Jimenez, Sergio A., Kissin, Eugene Y.   +3 more
core   +3 more sources

Improvement of mouth functional disability in systemic sclerosis patients over one year in a trial of fat transplantation versus adipose-derived stromal cells [PDF]

, 2016
Background. Systemic sclerosis (SSc) is a multisystem disease characterized by cutaneous and visceral fibrosis. Face and mouth changes include telangiectasia, sicca syndrome, and thinning and reduction of mouth width (microcheilia) and opening ...
CARELLA, SARA, FINO, PASQUALE, FIORAMONTI, Paolo, MARCHESE, Cinzia, ONESTI, Maria Giuseppina, SCUDERI, Nicolo'   +5 more
core   +4 more sources